Study of 1,235 Women Finds PCOS Does Not Raise Abnormal Ovarian Cyst Rates
Updated
Updated · ABC News · May 12
Study of 1,235 Women Finds PCOS Does Not Raise Abnormal Ovarian Cyst Rates
4 articles · Updated · ABC News · May 12
JAMA Internal Medicine published a study of 1,235 Finnish women finding those with PCOS had no higher rate of abnormal, non-cancerous ovarian cysts than women without the condition.
Among 1,012 women with PCOS and 223 controls, researchers found PCOS patients were 12 times more likely to have multiple antral follicles—small fluid-filled sacs often mistaken for cysts—but not more dominant follicles or abnormal cysts.
The authors said the results suggest women with PCOS do not need more frequent ultrasound screening for benign or pathological ovarian cysts solely because of the diagnosis.
PCOS affects about 1 in 8 women and can take up to a decade or more to diagnose, while raising risks tied to infertility, insulin resistance, type 2 diabetes and other metabolic problems.
Researchers and outside specialists said the findings bolster a global push to rename PCOS, arguing the current term wrongly centers ovaries and fuels confusion about the condition's broader health effects.
As PCOS is renamed for its metabolic nature, could a 'male form' of the disorder make the new name quickly obsolete?
With 70% of cases undiagnosed, can AI finally solve the massive diagnostic delay that has plagued women with this complex condition?
Beyond the name change, what tangible differences in treatment and insurance will the 170 million women with PMOS actually see?
From PCOS to PMOS: The 2026 Renaming and the Push for Holistic, Equitable Care in Women's Endocrine Health
Overview
In May 2026, Polycystic Ovary Syndrome (PCOS) was officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect the condition’s complex nature. The old name focused mainly on the ovaries and fertility, causing many people to overlook other important health issues. The new name highlights that PMOS involves not just the ovaries, but also broader endocrine and metabolic systems. This change encourages a more holistic understanding and care approach, helping both patients and healthcare providers recognize and address the full range of symptoms and risks linked to the condition.